Comparison of the effect of labetalol and dexmedetomidine in induction of control hypotension in patients with rhinoplasty

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141209020258N171

Enrollment

Registered

2022-01-16

Start date

2022-01-05

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhinoplasty.

Interventions

Intervention 1: Intervention group 1: We will infuse 0.3 milligram in kilogram in hours of labetalol during surgery. Intervention 2: Intervention group 2: We will infuse Dexmedetomidine 0.5 microgeram

Eligibility

Sex/Gender

All

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Age range 18 to 45 years Candidate patients for rhinoplasty surgery Body mass index 20 to 30 The duration of surgery is between 90 to 150 minutes No history of cardiovasculsar disease, pulmonary disease, renal disease and hepatic diseases No history of allergy to labetalol and dexmedetomidine No pregnancy and lactation ASA class I and II

Exclusion criteria

Exclusion criteria: For any reason, they have suffered cardiorespiratory arrest during previous surgeries

Design outcomes

Primary

Measure	Time frame
Sedation. Timepoint: Recovery. Method of measurement: Ramsay score.;Bleeding. Timepoint: During operation and recovery. Method of measurement: Observation,The amount of bleeding is reported on millilitre.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Behnam Mahmodie

Arak University of Medical Sciences

mahmodie@arakmu.ac.ir+98 86 3222 2003

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026